Disclaimer
We’re actively expanding Guideline Genius to cover the full UKMLA content map. You may notice some conditions not uploaded yet, or articles that only include diagnosis and management for now. For updates, follow us on Instagram @guidelinegenius.
We openly welcome any feedback or suggestions through the anonymous feedback box at the bottom of every article and we’ll do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 312

Bronchiolitis

NICE guideline [NG9] Bronchiolitis in children: diagnosis and management. Last updated: Aug 2021.

Background Information

Definition

A type of LRTI – particularly, with inflammation of the bronchioles – occuring in <2 y/o

Note that in those >2 y/o, usually large airways (bronchi) are affected – bronchitis.

Causes

Most commonly caused by respiratory syncytial virus (RSV)

Clinical Features

Occurs in <2 y/o:

  • More common in <1 y/o
  • Peak incidence at 3-6 months

Typical presentation:

  • Coryzal prodrome lasting 1-3 days
  • Followed by persistent cough

Examination findings:

  • Fever
  • Focal crackles and/or wheeze
  • Poor feeding
  • Respiratory distress features
    • Tachypnoea
    • Chest recession
    • Nasal flaring
    • Grunting
    • Cyanosis
    • Prolonged expiration phase

 

Young infants (esp. <6 weeks) may present atypically with apnoea and no classic signs.

Diagnosis Guidelines

Investigation and Diagnosis

Bronchiolitis should be diagnosed clinically:

NICE recommends to diagnose bronchiolitis if the baby or child has a coryzal prodrome lasting 1 to 3 days, followed by:

  • persistent cough and
  • either tachypnoea or chest recession (or both) and
  • either wheeze or crackles on chest auscultation (or both).

NICE explicitly says NOT to routinely perform a chest X-ray (as X-ray changes may mimic pneumonia). Only consider performing a chest X-ray if intensive care is being proposed.

The following features should raise suspicion of pneumonia over bronchiolitis:

  • Fever >39 °C (if present fever is typically <39 °C in bronchiolitis) and/or
  • Persistent focal crackles

Viral testing for RSV detection (inc. PCR and/or antigen detection assays on respiratory samples) is available, however, not necessary to diagnose bronchiolitis.

Management Guidelines

Admission Criteria

Admission to hospital is indicated if ANY of the following:

  • Apnoea
  • Hypoxia
    • SpO2 <90% in ≥6 weeks old
    • SpO2 <92% in <6 weeks old or those with underlying health conditions
  • Inadequate fluid intake (50-75% of usual volume)
  • Severe respiratory distress (e.g. grunting, marked chest recession, respiratory rate >70 / min)

 

The following risk factors are associated with more severe bronchiolitis (these patients are more likely to require admission):

  • Chronic lung disease
  • Haemodynamically significant congenital heart disease
  • <3 months
  • Premature birth (esp. <32 weeks)
  • Neuromuscular disorders
  • Immunodeficiency

Management

Mainstay of bronchiolitis management is supportive care

  • Respiratory support
    • Oxygen therapy if SpO2 <90% (in ≥6 weeks old) or SpO2 <92% (in <6 weeks old or those with underlying health conditions)
      • Initial: standard oxygen therapy via low-flow nasal cannula OR head box
      • Step-up: high-flow nasal cannula
    • Consider CPAP in those with impending respiratory failure

 

  • Feeding support
    • Consider nasogastric / orogastric tube or IV isotonic fluids if unable to tolerate oral fluids or insufficient intake

 

  • Consider upper airway suction if
    • Secretions are causing feeding difficulties or respiratory distress, or
    • Apnoea, even with no upper airway secretions

 

Do not offer the following to treat bronchiolitis:

  • Antibiotics
  • Bronchodilators
  • Corticosteroids
  • Montelukast
  • Hypertonic saline
  • Nebulised adrenaline

Prevention

Maternal RSV vaccination

Routine RSV vaccination in pregnancy was introduced in Sep 2024 in the UK [Ref]

  • All women offered RSV vaccination at 28 weeks gestation (at each pregnancy)
    • Provides passive infant immunity for the first 6 months of life

Immunoprophylaxis

Involves administration of a long-acting monoclonal antibody to infants

  • Approved agents in US/Europe → Palivizumab/Nirsevimab
  • Summarised indications [Ref]
    • All infants born during or entering their first RSV season AND/OR
    • At high-risk of severe disease

References

Original Guideline

Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD